DEVELOPMENT PROGRESS

Key foundations are already in place

healthy volunteers in the controlled study

260

capsules produced during development

66,000

manufacturing route established

UK GMP

reported founder-funded development

£700+

THE OPPORTUNITY

A differentiated story in a large consumer-health category

T-Booster combines an unusual biological focus, experienced scientific leadership, UK manufacturing readiness and a completed controlled study programme.

The commercial strategy should remain grounded in validated evidence, permitted health claims, product economics and realistic distribution assumptions.

Science-led positioning

A research narrative centred on immune health and healthy ageing.

01

Consumer-friendly format

A capsule product designed for straightforward daily use.

02

Multiple routes to market

Direct-to-consumer, B2B, pharmacy, practitioner and distribution channels.

03

Platform potential

The R&D and brand development capability may support future products.

04

COMMERCIAL ROADMAP

De-risk each stage before scaling

1

Complete analysis, scientific interpretation, publications and patent.

Finalize evidence

Regulatory readiness

Confirm labelling, claims, registrations, and market requirements.

2

3

Build inventory, fulfilment, customer support and compliant marketing.

Launch preparation

Market phase entry

Test acquisition, retention and channel economics before expansion.

4

BILLION-DOLLAR IMMUNOSUPPLEMENT MARKET

Worldwide demand for science-led immune support

The global immune health supplement market was valued at approximately $86 billion in 2024 and is projected to reach $132 billion by 2028, representing an estimated CAGR of 11.38%. Growth is being driven by ageing populations, rising awareness of immune health and increasing demand for science-led nutritional products.

T-Booster will initially focus on the UK, EU, USA and Bangladesh, where demand for immune-health and healthy-ageing products continues to grow.

T-BOOSTER MARKET OPPORTUNITY

A focused pathway to global market share

T-Booster aims to capture approximately 0.3% of the global market, representing potential annual revenue of around $48 million by 2028.

This target provides a conservative pathway for growth through clinical evidence, premium product positioning, international distribution and increasing consumer interest in immune health and healthy ageing.